SG3 Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

SG3 Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-5,000	Closed	-$729K	–	283
2022 Q2	$729K	Buy	+5,000	New	+$709K	0.09%	161
2022 Q1	–	Sell	-46,500	Closed	-$7.88M	–	931
2021 Q4	$7.88M	Buy	46,500 +14,900	+47%	+$2.77M	0.16%	117
2021 Q3	$5.97M	Buy	+31,600	New	+$5.93M	0.18%	114
2021 Q2	–	Sell	-12,500	Closed	-$1.76M	–	996
2021 Q1	$1.76M	Buy	+12,500	New	+$1.88M	0.04%	446
2020 Q4	–	Sell	-10,000	Closed	-$1.46M	–	995
2020 Q3	$1.46M	Buy	+10,000	New	+$1.42M	0.05%	337

Other funds holding ALNY

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

SG3 Management's ALNY Position: Q1 2022 in Review

SG3 Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2022, closing a stake of 17,000 shares — an estimated $2.59M sold.

SG3 Management first reported a position in ALNY in Q1 2021 and held it in 4 quarters. The position peaked at $7.6M in Q3 2021. 444 funds tracked by Wall St. Rank hold ALNY as of Q1 2022.

SG3 Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
SG3 Management sold 17,000 Alnylam Pharmaceuticals shares in Q1 2022, an estimated $2.59M.
SG3 Management first reported a position in Alnylam Pharmaceuticals in Q1 2021 and held it in 4 quarters.
SG3 Management's Alnylam Pharmaceuticals position peaked at $7.6M in Q3 2021.
444 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2022.

Based on SG3 Management's 13F filing for Q1 2022, filed 16 May 2022.